About Spearpoint Analytics – AI for prostate cancer diagnostics
Spearpoint Analytics was founded in Stockholm in 2019. We combine AI and clinical expertise for precision medicine in prostate cancer diagnostics.
Free digital meeting. You decide whether to go ahead.
What we do
Every year, thousands of Swedish men receive a prostate cancer diagnosis based on a method that can be misleading. Should you have surgery, radiotherapy or wait? The decision is of vital importance, and we want it to be based on the best possible analysis. Spearpoint Analytics was founded in 2019 with a single focus: to increase precision in the diagnosis of prostate cancer. We combine AI and clinical expertise to give both doctors and patients a more reliable basis for decisions.
Our products:
- PCAI (Prostate Cancer Aggressiveness Index): an AI-based analysis that assesses the aggressiveness of the tumour with a reproducible index of 1–100.
- SPCD (Spearpoint Cancer Detector): an AI solution that identifies cancerous tissue in a biopsy with over 95% precision (AUROC 0.94).
Based on outcome data
Our AI models have been developed in close collaboration with Martini-Klinik in Hamburg, one of the world's leading clinics for prostate cancer treatment. An immensely large database, 17,700 patients with up to 20 years of follow-up, has trained our AI model How PCAI works.
PCAI already today outperforms experienced specialists in uropathology on all external test cohorts. And the model's potential for further development is considerable, towards approaching a complete diagnostic instrument.
2019
founded in Stockholm
Canonical facts
17,700
patients in the database behind the model
Regeldok v1.0 §4
1–100
PCAI's index across seven risk levels
Reduced human suffering – savings for society
The goal: that every man affected by prostate cancer should receive the most precise diagnosis possible, and thereby the most appropriate treatment, or, where possible, the reassuring message that radical treatment can wait, or may never need to be carried out at all Surveillance vs. surgery. That will reduce suffering and save large costs to society.
What you will find here
Everything under About us
- The teamMeet the people behind Spearpoint: urologists, AI researchers and clinical experts from Uppsala, Hamburg and Stockholm.
- Our storyFrom Professor Sauter's biobank in 2003 to the market launch in 2025. Read the story behind PCAI and Spearpoint Analytics, year by year.
- PartnersSpearpoint works with Martini-Klinik in Hamburg, Akademiska sjukhuset in Uppsala, Uppsala University and UKE Hamburg – the institutions behind PCAI.
- For investorsSpearpoint Analytics addresses a global market with 1.4 million new prostate cancer cases a year. Read about the business model and the growth plan.
- Support the developmentWould you like to contribute to the development of AI-based prostate cancer diagnostics? We are looking for a few committed people who want to support the research.
It is wise to ask
You are welcome to contact us to discuss a second opinion. The meeting is free of charge. If you feel afterwards that this is right for you, you can simply order a second opinion.
Related: Our story | The team | Partners | For investors | Support the development